Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 10/20 | 0.78 |
| ▸ | EGFR | P00533 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847685 | 1.00 | DNM1 (0.78) | DNM1EGFRKMT2AMEN1MAPT | |
| SCHEMBL846328 | 0.91 | DNM1 (0.72) | DNM1EGFRKMT2AMEN1MAPT | |
| SCHEMBL846327 | 0.91 | DNM1 (0.72) | DNM1EGFRKMT2AMEN1MAPT | |
| SCHEMBL846146 | 0.88 | DNM1 (0.74) | DNM1EGFRKMT2AMEN1MAPT | |
| SCHEMBL846147 | 0.88 | DNM1 (0.74) | DNM1EGFRKMT2AMEN1MAPT | |
| SCHEMBL847409 | 0.87 | DNM1 (0.73) | DNM1EGFRKMT2AMEN1MAPT | |
| SCHEMBL847410 | 0.87 | DNM1 (0.73) | DNM1EGFRKMT2AMEN1MAPT | |
| SCHEMBL848238 | 0.86 | DNM1 (1.00) | DNM1EGFRKMT2AMEN1MAPT | |
| SCHEMBL848237 | 0.86 | DNM1 (1.00) | DNM1EGFRKMT2AMEN1MAPT | |
| SCHEMBL846345 | 0.83 | EGFR (0.73) | DNM1EGFRKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2911692-B1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | UNIV QUEENSLAND (AU) | 2019-08-21 | — | — | EP | disclosed |
| US-10253107-B2 | Use of endocytosis inhibitors and antibodies for cancer therapy | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-04-09 | — | — | US | disclosed |
| US-20150284469-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-10-08 | — | — | US | disclosed |
| EP-2911692-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | The University of Queensland (AU) | 2015-09-02 | — | — | EP | disclosed |
| EP-2432465-B1 | USE OF DYNAMIN RING STABILIZERS | CHILDREN S MEDICAL RES INST (AU) | 2015-07-22 | — | — | EP | disclosed |
| US-8809386-B2 | Use of dynamin ring stabilizers | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2014-08-19 | — | — | US | disclosed |
| WO-2014063205-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-05-01 | — | — | WO | disclosed |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2432465-A1 | USE OF DYNAMIN RING STABILIZERS | Children's Medical Research Institute (AU) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010132959-A1 | USE OF DYNAMIN RING STABILIZERS | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2010-11-25 | — | — | WO | disclosed |
| EP-1691800-A4 | METHODS AND AGENTS FOR INHIBITING DYNAMIN-DEPENDENT ENDOCYTOSIS | UNIV NEWCASTLE RES ASS (AU) | 2009-03-18 | — | — | EP | disclosed |
| US-20070225363-A1 | Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis | THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOCIATES LTD. (AU) | 2007-09-27 | — | — | US | disclosed |
| EP-1691800-A1 | METHODS AND AGENTS FOR INHIBITING DYNAMIN-DEPENDENT ENDOCYTOSIS | THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOCIATES LIMITED (AU) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005049009-A1 | METHODS AND AGENTS FOR INHIBITING DYNAMIN-DEPENDENT ENDOCYTOSIS | THE UNIVERSITY OF NEWCASTLE RESEARCH ASSOCIATES LIMITED (AU) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253107-B2 | Use of endocytosis inhibitors and antibodies for cancer therapy | CLINT1, CLTC, DNM1L | DNM1 4/4885EGFR 12/4885KMT2A 2803/4885 |
| US-20150284469-A1 | USE OF ENDOCYTOSIS INHIBITORS AND ANTIBODIES FOR CANCER THERAPY | CLINT1, CLTC, DNM1L | DNM1 4/4885EGFR 12/4885KMT2A 2803/4885 |
| US-20120122968-A1 | USE OF DYNAMIN RING STABILIZERS | DNM1L, DNM1, DNM2 | DNM1 2/4885EGFR 3915/4885KMT2A 3497/4885 |
| US-20070225363-A1 | Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis | DNM1, DNM1L, DNM2 | DNM1 1/4885EGFR 225/4885KMT2A 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.